Meningococcal meningitis banner

Meningococcal meningitis

Meningococcal meningitis and septicaemia is a rare but potentially devastating and unpredictable bacterial infection. 1 While meningococcal disease mainly affects children below the age of five and adolescents, it can affect healthy individual at any age. 1,2 The disease can claim a life in as little as 24 hours or cause severe long-term sequelae (such as hearing loss, brain damage and disability) with devastating effects on the individuals and their families. 3,4

At Sanofi Pasteur, we believe in a world where no one suffers or dies from vaccine preventable diseases. For over 45 years, we have been at the forefront in combating meningococcal epidemics and in driving meningococcal vaccine evolution, to further expand protection of individuals worldwide.

Our fight against meningococcal meningitis
Our fight against meningococcal meningitis
Twitter Cards
Most cases can be prevented through vaccination

Sumeyra - Meningococcal disease survivor

Routine Vaccination Programs

Routine Vaccination Programs

Despite the unpredictability and severity of the disease, given the low incidence of the disease, routine immunization programs tend to focus on the populations with higher risk of meningococcal meningitis leaving room for outbreaks in unprotected populations. 5
Sanofi Pasteur's Legacy

Sanofi Pasteur’s legacy

To know more about meningococcal disease

World free from meningitis by 2030

We are committed to playing our part in achieving the WHO and Meningitis Research Foundation stated vision of a world free from meningitis by 2030. 
Meningitis research foundation
Defeating meningitis by 2030


  1. European Centre for Disease Prevention and Control (ECDC). Surveillance Atlas of Infectious Diseases. Available at [accessed November 2020].
  2. WHO. Meningococcal meningitis [accessed November 2020].
  3. Beebeejaun, K et al. Invasive meningococcal disease: Timing and cause of death in England, 2008–2015. Journal of Infection, March 2020 [accessed November 2020].
  4. Meningitis Research Foundation. After effects [accessed November 2020].
  5. Sanofi Pasteur (2020). Meningococcal Disease in Europe: A Rare but Devastating Disease.